Pfiz­er spin­out Spring­Works gets FDA pri­or­i­ty re­view for lead drug

A Pfiz­er spin­out is get­ting a quick date with reg­u­la­tors for its “pipeline-in-a-prod­uct.”

Spring­Works Ther­a­peu­tics an­nounced Mon­day morn­ing that the FDA grant­ed nirogace­s­tat, the biotech’s lead can­di­date, pri­or­i­ty re­view for adults with desmoid tu­mors. Should the drug win ap­proval, it would be the com­pa­ny’s first since be­ing spun out of Pfiz­er five and a half years ago.

The FDA will make a de­ci­sion by Aug. 27, Spring­Works said in a press re­lease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER